Table 3 Adverse reactions to peanut OIT while on Ketotifen (day 2-week 4)
From: Effect of ketotifen premedication on adverse reactions during peanut oral immunotherapy
Adverse reactions and treatment | Build-up doses in clinic | Home doses | ||
|---|---|---|---|---|
Ketotifen | Placebo | Ketotifen | Placebo | |
Total no. of doses of OIT, n | 4 | 2 | 108 | 33 |
Total no. of missed OIT doses, n | - | - | - | - |
Total no. of patients reporting symptoms | 3 | 1 | 4 | 2 |
Total no. of doses with symptoms, n (% of OIT doses) | 3/4 (75%) | 2/2 (100%) | 54/108 (50%) | 27/33 (82%) |
Anaphylaxis, n (% of OIT doses) | - | - | 1/108 (1%) | 1/33 (3%) |
Symptoms n, (% of OIT doses) | Ketotifen | Placebo | Ketotifen | Placebo |
Gastrointestinal | 3/4 (75%) | 2/2 (100%) | 50/108 (46%) | 27/33 (82%) |
Cutaneous | - | 1/2 (50%) | 1/108 (1%) | 6/33 (18%) |
Lower respiratory | - | - | 6/108 (6%) | 2/33 (6%) |
Upper respiratory | - | - | 2/108 (2%) | - |
Oropharyngeal | - | - | 1/108 (1%) | - |
Cardiovascular | - | - | - | - |
Other | - | - | 14/108 (13%)B | 2/33 (6%)B |
Treatment n, (% of OIT doses) | Ketotifen | Placebo | Ketotifen | Placebo |
Epinephrine | - | - | - | 1/33 (3%) |
Diphenhydramine | - | - | 1/108 (1%) | 1/33 (3%) |
Cetirizine** | 1/4 (25%) | - | 7/108 (6%) | 5/33 (15%) |
Prednisone | - | - | - | 1/33 (3%) |
Salbutamol or other inhaled medication | - | - | 1/108 (1%) | - |